Controlling angiogenesis by two unique TGF-β type I receptor signaling pathways

Histology and Histopathology

Volumn 26, Issue 9, 2011, Pages 1219-1230

  Orlova, Valeria V ^a   Liu, Zhen ^a   Goumans, Marie José ^a   ten Dijke, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; BMP; Hereditary hemorrhagic telangiectasia; Preeclampsia; Pulmonary arterial hypertension

Indexed keywords

PROTEIN SERINE THREONINE KINASE; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANGIOGENESIS; ANIMAL; BLOOD VESSEL; CYTOLOGY; ENDOTHELIUM CELL; GENETICS; HUMAN; LYMPHANGIOGENESIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ANIMALS; BLOOD VESSELS; ENDOTHELIAL CELLS; HUMANS; LYMPHANGIOGENESIS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

MUS;

EID: 80053186583     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Antonelli-Orlidge A., Saunders K.B., Smith S.R. and D'Amore P.A. (1989). An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes. Proc. Natl. Acad. Sci. USA 86, 4544-4548.
2. Armulik A., Abramsson A. and Betsholtz C. (2005). Endothelial/pericyte interactions. Circ. Res. 97, 512-523.
3. Arthur H.M., Ure J., Smith A.J., Renforth G., Wilson D.I., Torsney E., Charlton R., Parums D.V., Jowett T., Marchuk D.A., Burn J. and Diamond A.G. (2000). Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol. 217, 42-53.
4. Atkinson C., Stewart S., Upton P.D., Machado R., Thomson J.R., Trembath R.C. and Morrell N.W. (2002). Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672-1678.
5. Berg J.N., Gallione C.J., Stenzel T.T., Johnson D.W., Allen W.P., Schwartz C.E., Jackson C.E., Porteous M.E. and Marchuk D.A. (1997). The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am. J. Hum. Genet. 61, 60-67.
6. Bergers G. and Song S. (2005). The role of pericytes in blood-vessel formation and maintenance. Neuro. Oncol. 7, 452-464.
7. Bernabeu C., Conley B.A. and Vary C.P. (2007). Novel biochemical pathways of endoglin in vascular cell physiology. J. Cell Biochem. 102, 1375-1388.
8. Bot P.T., Hoefer I.E., Sluijter J.P., van Vliet P., Smits A.M., Lebrin F., Moll F., de Vries J.P., Doevendans P., Piek J.J., Pasterkamp G. and Goumans M.J. (2009). Increased expression of the transforming growth factor-β signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke 40, 439-447.
9. Bourdeau A., Dumont D.J. and Letarte M. (1999). A murine model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 104, 1343-1351.
10. Brooke B.S., Habashi J.P., Judge D.P., Patel N., Loeys B. and Dietz H.C. 3rd. (2008). Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N. Engl. J. Med. 358, 2787-2795.
11. Brown M.A., Zhao Q., Baker K.A., Naik C., Chen C., Pukac L., Singh M., Tsareva T., Parice Y., Mahoney A., Roschke V., Sanyal I. and Choe S. (2005). Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J. Biol. Chem. 280, 25111-25118.
12. Bueno L., de Alwis D.P., Pitou C., Yingling J., Lahn M., Glatt S. and Troconiz I.F. (2008). Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. Eur. J. Cancer. 44, 142-150.
13. Carmeliet P. (2005). Angiogenesis in life, disease and medicine. Nature 438, 932-936.
14. Castanares C., Redondo-Horcajo M., Magan-Marchal N., ten Dijke P., Lamas S. and Rodriguez-Pascual F. (2007). Signaling by ALK5 mediates TGF-β-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J. Cell Sci. 120, 1256-1266.
15. Chan M.C., Hilyard A.C., Wu C., Davis B.N., Hill N.S., Lal A., Lieberman J., Lagna G. and Hata A. (2010). Molecular basis for antagonism between PDGF and the TGFβ family of signalling pathways by control of miR-24 expression. EMBO J. 29, 559-573.
16. Chen S. and Lechleider R.J. (2004). Transforming growth factor-β- induced differentiation of smooth muscle from a neural crest stem cell line. Circ. Res. 94, 1195-1202.
17. Cohn R.D., van Erp C., Habashi J.P., Soleimani A.A., Klein E.C., Lisi M.T., Gamradt M., ap Rhys C.M., Holm T.M., Loeys B.L., Ramirez F., Judge D.P., Ward C.W. and Dietz H.C. (2007). Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13, 204-210.
18. Collod-Beroud G., Le Bourdelles S., Ades L., Ala-Kokko L., Booms P., Boxer M., Child A., Comeglio P., De Paepe A., Hyland J.C., Holman K., Kaitila I., Loeys B., Matyas G., Nuytinck L., Peltonen L., Rantamaki T., Robinson P., Steinmann B., Junien C., Beroud C. and Boileau C. (2003). Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum. Mutat. 22, 199-208.
19. Cunha S.I., Pardali E., Thorikay M., Anderberg C., Hawinkels L., Goumans M.J., Seehra J., Heldin C.H., ten Dijke P. and Pietras K. (2010). Genetic and pharmacological targeting of activin receptorlike kinase 1 impairs tumor growth and angiogenesis. J. Exp. Med. 207, 85-100.
20. Darland D.C. and D'Amore P.A. (2001). TGF β is required for the formation of capillary-like structures in three-dimensional cocultures of 10T1/2 and endothelial cells. Angiogenesis 4, 11-20.
21. David L., Mallet C., Keramidas M., Lamande N., Gasc J.M., Dupuis-Girod S., Plauchu H., Feige J.J. and Bailly S. (2008). Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res. 102, 914-922.
22. David L., Mallet C., Mazerbourg S., Feige J.J. and Bailly S. (2007). Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109, 1953-1961.
23. Davies R.J. and Morrell N.W. (2008). Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor. Chest 134, 1271-1277.
24. Davis B.N., Hilyard A.C., Lagna G. and Hata A. (2008). SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454, 56-61.
25. Dickson M.C., Martin J.S., Cousins F.M., Kulkarni A.B., Karlsson S. and Akhurst R.J. (1995). Defective haematopoiesis and vasculogenesis in transforming growth factor-β 1 knock out mice. Development 121, 1845-1854.
26. Domenga V., Fardoux P., Lacombe P., Monet M., Maciazek J., Krebs L.T., Klonjkowski B., Berrou E., Mericskay M., Li Z., Tournier-Lasserve E., Gridley T. and Joutel A. (2004). Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 18, 2730-2735.
27. Dorai H., Vukicevic S. and Sampath T.K. (2000). Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J. Cell Physiol. 184, 37-45.
28. Dupuis-Girod S., Bailly S. and Plauchu H. (2010). Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J. Thromb. Haemost. 8, 1447-1456.
29. Gaengel K., Genove G., Armulik A. and Betsholtz C. (2009). Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 630-638.
30. Gallione C.J., Repetto G.M., Legius E., Rustgi A.K., Schelley S.L., Tejpar S., Mitchell G., Drouin E., Westermann C.J. and Marchuk D.A. (2004). A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363, 852-859.
31. Gamble J.R., Khew-Goodall Y. and Vadas M.A. (1993). Transforming growth factor-β inhibits E-selectin expression on human endothelial cells. J. Immunol. 150, 4494-4503.
32. Goumans M.J. and Mummery C. (2000). Functional analysis of the TGFβ receptor/Smad pathway through gene ablation in mice. Int. J. Dev. Biol. 44, 253-265.
33. Goumans M.J., Zwijsen A., van Rooijen M.A., Huylebroeck D., Roelen B.A. and Mummery C.L. (1999). Transforming growth factor-β signalling in extraembryonic mesoderm is required for yolk sac vasculogenesis in mice. Development 126, 3473-3483.
34. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P. and ten Dijke P. (2002). Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J. 21, 1743-1753.
35. Goumans M.J., Valdimarsdottir G., Itoh S., Lebrin F., Larsson J., Mummery C., Karlsson S. and ten Dijke P. (2003). Activin receptorlike kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol. Cell 12, 817-828.
36. Goumans M.J., van Zonneveld A.J. and ten Dijke P. (2008). Transforming growth factor β-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc. Med. 18, 293-298.
37. Goumans M.J., Liu Z. and ten Dijke P. (2009). TGF-β signaling in vascular biology and dysfunction. Cell Res. 19, 116-127.
38. Govani F.S. and Shovlin C.L. (2009). Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur. J. Hum. Genet. 17, 860-871.
39. Haitjema T., Balder W., Disch F.J. and Westermann C.J. (1996a). Epistaxis in hereditary haemorrhagic telangiectasia. Rhinology 34, 176-178.
40. Haitjema T., Westermann C.J., Overtoom T.T., Timmer R., Disch F., Mauser H. and Lammers J.W. (1996b). Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications, and treatment. Arch. Intern. Med. 156, 714-719.
41. Hansmann G., de Jesus Perez V.A., Alastalo T.P., Alvira C.M., Guignabert C., Bekker J.M., Schellong S., Urashima T., Wang L., Morrell N.W. and Rabinovitch M. (2008). An antiproliferative BMP- 2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J. Clin. Invest. 118, 1846-1857.
42. Harrison R.E., Berger R., Haworth S.G., Tulloh R., Mache C.J., Morrell N.W., Aldred M.A. and Trembath R.C. (2005). Transforming growth factor-β receptor mutations and pulmonary arterial hypertension in childhood. Circulation 111, 435-441.
43. Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J., Machado R.D., Elliott C.G., Robbins I.M., Olschewski H., McLaughlin V., Gruenig E., Kermeen F., Halme M., Raisanen- Sokolowski A., Laitinen T., Morrell N.W. and Trembath R.C. (2003). Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J. Med. Genet. 40, 865-871.
44. Hawinkels L.J., Kuiper P., Wiercinska E., Verspaget H.W., Liu Z., Pardali E., Sier C.F. and ten Dijke P. (2010). Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer. Res. 70, 4141-4150.
45. Heldin C.H., Miyazono K. and ten Dijke P. (1997). TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471.
46. Hirschi K.K. and D'Amore P.A. (1996). Pericytes in the microvasculature. Cardiovasc. Res. 32, 687-698.
47. Hirschi K.K., Rohovsky S.A. and D'Amore P.A. (1998). PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cellinduced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol. 141, 805-814.
48. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., Christman B.W., Weir E.K., Eickelberg O., Voelkel N.F. and Rabinovitch M. (2004). Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 13S-24S.
49. Inman G.J., Nicolas F.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D., Laping N.J. and Hill C.S. (2002). SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65-74.
50. Kobayashi K., Yokote K., Fujimoto M., Yamashita K., Sakamoto A., Kitahara M., Kawamura H., Maezawa Y., Asaumi S., Tokuhisa T., Mori S. and Saito Y. (2005). Targeted disruption of TGF-β-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. Circ. Res. 96, 904-912.
51. Kurpinski K., Lam H., Chu J., Wang A., Kim A., Tsay E., Agrawal S., Schaffer D.V. and Li S. (2010). Transforming growth factor-β and notch signaling mediate stem cell differentiation into smooth muscle cells. Stem Cells 28, 734-742.
52. Lacro R.V., Dietz H.C., Wruck L.M., Bradley T.J., Colan S.D., Devereux R.B., Klein G.L., Li J.S., Minich L.L., Paridon S.M., Pearson G.D., Printz B.F., Pyeritz R.E., Radojewski E., Roman M.J., Saul J.P., Stylianou M.P. and Mahony L. (2007). Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am. Heart. J. 154, 624-631.
53. Laffitte E. and Revuz J. (2004). Thalidomide: an old drug with new clinical applications. Expert Opin. Drug Saf. 3, 47-56.
54. Lagna G., Nguyen P.H., Ni W. and Hata A. (2006). BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 291, L1059-1067.
55. Lagna G., Ku M.M., Nguyen P.H., Neuman N.A., Davis B.N. and Hata A. (2007). Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. J. Biol. Chem. 282, 37244-37255.
56. Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R., Phillips J.A. 3rd, Loyd J.E., Nichols W.C. and Trembath R.C. (2000). Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat. Genet. 26, 81-84.
57. Lastres P., Letamendia A., Zhang H., Rius C., Almendro N., Raab U., Lopez L.A., Langa C., Fabra A., Letarte M. and Bernabeu C. (1996). Endoglin modulates cellular responses to TGF-β 1. J. Cell Biol. 133, 1109-1121.
58. Lebrin F., Goumans M.J., Jonker L., Carvalho R.L., Valdimarsdottir G., Thorikay M., Mummery C., Arthur H.M. and ten Dijke P. (2004). Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J. 23, 4018-4028.
59. Lebrin F., Srun S., Raymond K., Martin S., van den Brink S., Freitas C., Breant C., Mathivet T., Larrivee B., Thomas J.L., Arthur H.M., Westermann C.J., Disch F., Mager J.J., Snijder R.J., Eichmann A. and Mummery C.L. (2010). Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat. Med. 16, 420-428.
60. Lechleider R.J., Ryan J.L., Garrett L., Eng C., Deng C., Wynshaw-Boris A. and Roberts A.B. (2001). Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev. Biol. 240, 157-167.
61. Li H.Y., McMillen W.T., Heap C.R., McCann D.J., Yan L., Campbell R.M., Mundla S.R., King C.H., Dierks E.A., Anderson B.D., Britt K.S., Huss K.L., Voss M.D., Wang Y., Clawson D.K., Yingling J.M. and Sawyer J.S. (2008). Optimization of a dihydropyrrolopyrazole series of transforming growth factor-β type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-β receptor type I inhibitor as antitumor agent. J. Med. Chem. 51, 2302-2306.
62. Lindeman J.H., Ashcroft B.A., Beenakker J.W., van Es M., Koekkoek N.B., Prins F.A., Tielemans J.F., Abdul-Hussien H., Bank R.A. and Oosterkamp T.H. (2010). Distinct defects in collagen microarchitecture underlie vessel-wall failure in advanced abdominal aneurysms and aneurysms in Marfan syndrome. Proc. Natl. Acad. Sci. U S A 107, 862-865.
63. Liu H., Kennard S. and Lilly B. (2009a). NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. Circ. Res. 104, 466-475.
64. Liu Z., Kobayashi K., van Dinther M., van Heiningen S.H., Valdimarsdottir G., van Laar T., Scharpfenecker M., Lowik C.W., Goumans M.J., Ten Dijke P. and Pardali E. (2009b). VEGF and inhibitors of TGFβ type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression. J. Cell Sci. 122, 3294-3302.
65. Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A., Spevak P.J., Cameron D.E., De Backer J., Hellemans J., Chen Y., Davis E.C., Webb C.L., Kress W., Coucke P., Rifkin D.B., De Paepe A.M. and Dietz H.C. (2005). A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 37, 275-281.
66. Loeys B.L., Schwarze U., Holm T., Callewaert B.L., Thomas G.H., Pannu H., De Backer J.F., Oswald G.L., Symoens S., Manouvrier S., Roberts A.E., Faravelli F., Greco M.A., Pyeritz R.E., Milewicz D.M., Coucke P.J., Cameron D.E., Braverman A.C., Byers P.H., De Paepe A.M. and Dietz H.C. (2006). Aneurysm syndromes caused by mutations in the TGF-β receptor. N. Engl. J. Med. 355, 788-798.
67. Lux A., Salway F., Dressman H.K., Kroner-Lux G., Hafner M., Day P.J., Marchuk D.A. and Garland J. (2006). ALK1 signalling analysis identifies angiogenesis related genes and reveals disparity between TGF-β and constitutively active receptor induced gene expression. BMC Cardiovasc. Disord. 6, 13.
68. Ma J., Wang Q., Fei T., Han J.D. and Chen Y.G. (2007). MCP-1 mediates TGF-β-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 109, 987-994.
69. Machado R.D., Eickelberg O., Elliott C.G., Geraci M.W., Hanaoka M., Loyd J.E., Newman J.H., Phillips J.A. 3rd, Soubrier F., Trembath R.C. and Chung W.K. (2009). Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54, S32-42.
70. Machado R.D., Pauciulo M.W., Thomson J.R., Lane K.B., Morgan N.V., Wheeler L., Phillips J.A. 3rd, Newman J., Williams D., Galie N., Manes A., McNeil K., Yacoub M., Mikhail G., Rogers P., Corris P., Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E., Trembath R.C. and Nichols W.C. (2001). BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68, 92-102.
71. Mahmoud M., Allinson K.R., Zhai Z., Oakenfull R., Ghandi P., Adams R.H., Fruttiger M. and Arthur H.M. (2010). Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ. Res. 106, 1425-1433.
72. Mancini M.L., Verdi J.M., Conley B.A., Nicola T., Spicer D.B., Oxburgh L.H. and Vary C.P. (2007). Endoglin is required for myogenic differentiation potential of neural crest stem cells. Dev. Biol. 308, 520-533.
73. Matt P., Schoenhoff F., Habashi J., Holm T., Van Erp C., Loch D., Carlson O.D., Griswold B.F., Fu Q., De Backer J., Loeys B., Huso D.L., McDonnell N.B., Van Eyk J.E. and Dietz H.C. (2009). Circulating transforming growth factor-β in Marfan syndrome. Circulation 120, 526-532.
74. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., Libermann T.A., Morgan J.P., Sellke F.W., Stillman I.E., Epstein F.H., Sukhatme V.P. and Karumanchi S.A. (2003). Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658.
75. McAllister K.A., Grogg K.M., Johnson D.W., Gallione C.J., Baldwin M.A., Jackson C.E., Helmbold E.A., Markel D.S., McKinnon W.C., Murrell J., McCormick M.K., Pericak-Vance M.A., Heutink P., Oostra B.A., Haitjema T., Westerman C.J.J., Porteous M.E., Guttmacher A.E., Letarte M. and Marchuk D.A. (1994). Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 8, 345-351.
76. Medici D., Shore E.M., Lounev V.Y., Kaplan F.S., Kalluri R. and Olsen B.R. (2010). Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 16, 1400-1406.
77. Mizuguchi T. and Matsumoto N. (2007). Recent progress in genetics of Marfan syndrome and Marfan-associated disorders. J. Hum. Genet. 52, 1-12.
78. Morrell N.W., Yang X., Upton P.D., Jourdan K.B., Morgan N., Sheares K.K. and Trembath R.C. (2001). Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β(1) and bone morphogenetic proteins. Circulation 104, 790-795.
79. Morrell N.W., Adnot S., Archer S.L., Dupuis J., Jones P.L., MacLean M.R., McMurtry I.F., Stenmark K.R., Thistlethwaite P.A., Weissmann N., Yuan J.X. and Weir E.K. (2009). Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54, S20-31.
80. Moustakas A. and Heldin C.H. (2009). The regulation of TGFβ signal transduction. Development 136, 3699-3714.
81. Neptune E.R., Frischmeyer P.A., Arking D.E., Myers L., Bunton T.E., Gayraud B., Ramirez F., Sakai L.Y. and Dietz H.C. (2003). Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33, 407-411.
82. Niessen K., Zhang G., Ridgway J.B., Chen H. and Yan M. (2009). ALK1 signaling regulates early postnatal lymphatic vessel development. Blood.
83. Nishimura G., Manabe I., Tsushima K., Fujiu K., Oishi Y., Imai Y., Maemura K., Miyagishi M., Higashi Y., Kondoh H. and Nagai R. (2006). DeltaEF1 mediates TGF-β signaling in vascular smooth muscle cell differentiation. Dev. Cell 11, 93-104.
84. Obreo J., Diez-Marques L., Lamas S., Duwell A., Eleno N., Bernabeu C., Pandiella A., Lopez-Novoa J.M. and Rodriguez-Barbero A. (2004). Endoglin expression regulates basal and TGF-β1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell. Physiol. Biochem. 14, 301-310.
85. Oh S.P., Seki T., Goss K.A., Imamura T., Yi Y., Donahoe P.K., Li L., Miyazono K., ten Dijke P., Kim S. and Li E. (2000). Activin receptorlike kinase 1 modulates transforming growth factor-β 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA 97, 2626-2631.
86. Owens G.K., Kumar M.S. and Wamhoff B.R. (2004). Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767-801.
87. Pardali E. and ten Dijke P. (2009). Transforming growth factor-β signaling and tumor angiogenesis. Front. Biosci. 14, 4848-4861.
88. Park S.O., Lee Y.J., Seki T., Hong K.H., Fliess N., Jiang Z., Park A., Wu X., Kaartinen V., Roman B.L. and Oh S.P. (2008). ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 111, 633-642.
89. Park S.O., Wankhede M., Lee Y.J., Choi E.J., Fliess N., Choe S.W., Oh S.H., Walter G., Raizada M.K., Sorg B.S. and Oh S.P. (2009). Realtime imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 119, 3487-3496.
90. Pepper M.S. (1997). Transforming growth factor-β: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 8, 21-43.
91. Redondo S., Ruiz E., Santos-Gallego C.G., Padilla E. and Tejerina T. (2005). Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-β1, and a Smad2-dependent mechanism. Diabetes 54, 811-817.
92. Redondo S., Ruiz E., Gordillo-Moscoso A., Navarro-Dorado J., Ramajo M., Carnero M., Reguillo F., Rodriguez E. and Tejerina T. (2010). Role of TGF-β1 and MAP kinases in the antiproliferative effect of aspirin in human vascular smooth muscle cells. PLoS One 5, e9800.
93. Rudini N., Felici A., Giampietro C., Lampugnani M., Corada M., Swirsding K., Garre M., Liebner S., Letarte M., ten Dijke P. and Dejana E. (2008). VE-cadherin is a critical endothelial regulator of TGF-β signalling. EMBO J. 27, 993-1004.
94. Santiago F.S., Lowe H.C., Kavurma M.M., Chesterman C.N., Baker A., Atkins D.G. and Khachigian L.M. (1999). New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat. Med. 5, 1438.
95. Sawyer J.S., Anderson B.D., Beight D.W., Campbell R.M., Jones M.L., Herron D.K., Lampe J.W., McCowan J.R., McMillen W.T., Mort N., Parsons S., Smith E.C., Vieth M., Weir L.C., Yan L., Zhang F. and Yingling J.M. (2003). Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J. Med. Chem. 46, 3953-3956.
96. Scharpfenecker M., van Dinther M., Liu Z., van Bezooijen R.L., Zhao Q., Pukac L., Lowik C.W. and ten Dijke P. (2007). BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 120, 964-972.
97. Scherner O., Meurer S.K., Tihaa L., Gressner A.M. and Weiskirchen R. (2007). Endoglin differentially modulates antagonistic transforming growth factor-β1 and BMP-7 signaling. J. Biol. Chem. 282, 13934-13943.
98. Shao E.S., Lin L., Yao Y. and Bostrom K.I. (2009). Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114, 2197-2206.
99. Sinha S., Hoofnagle M.H., Kingston P.A., McCanna M.E. and Owens G.K. (2004). Transforming growth factor-β1 signaling contributes to development of smooth muscle cells from embryonic stem cells. Am. J. Physiol. Cell Physiol. 287, C1560-1568.
100. Smith W.B., Noack L., Khew-Goodall Y., Isenmann S., Vadas M.A. and Gamble J.R. (1996). Transforming growth factor-β 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J. Immunol. 157, 360-368.
101. Sorensen L.K., Brooke B.S., Li D.Y. and Urness L.D. (2003). Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFβ coreceptor. Dev. Biol. 261, 235-250.
102. Srinivasan S., Hanes M.A., Dickens T., Porteous M.E., Oh S.P., Hale L.P. and Marchuk D.A. (2003). A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum. Mol. Genet. 12, 473-482.
103. Star G.P., Giovinazzo M. and Langleben D. (2010). Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells A potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension. Microvasc. Res. 80, 349-354.
104. Suzuki Y., Ohga N., Morishita Y., Hida K., Miyazono K. and Watabe T. (2010). BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J. Cell Sci. 123, 1684-1692.
105. ten Dijke P. and Arthur H.M. (2007). Extracellular control of TGFβ signalling in vascular development and disease. Nat. Rev. Mol. Cell. Biol. 8, 857-869.
106. ten Dijke P. and Hill C.S. (2004). New insights into TGF-β-Smad signalling. Trends Biochem. Sci. 29, 265-273.
107. Tian F., Zhou A.X., Smits A.M., Larsson E., Goumans M.J., Heldin C.H., Boren J. and Akyurek L.M. (2010). Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro. Biochem. Biophys. Res. Commun. 392, 283-288.
108. Upton P.D., Davies R.J., Trembath R.C. and Morrell N.W. (2009). Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J. Biol. Chem. 284, 15794-15804.
109. Urness L.D., Sorensen L.K. and Li D.Y. (2000). Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat. Genet. 26, 328-331.
110. van den Driesche S., Mummery C.L. and Westermann C.J. (2003). Hereditary hemorrhagic telangiectasia: an update on transforming growth factor β signaling in vasculogenesis and angiogenesis. Cardiovasc. Res. 58, 20-31.
111. van Meeteren L.A., Goumans, M.J. and ten Dijke P. (2011). TGF-β Receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr. Pharma. Biotechnol. (in press).
112. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., Bdolah Y., Lim K.H., Yuan H.T., Libermann T.A., Stillman I.E., Roberts D., D'Amore P.A., Epstein F.H., Sellke F.W., Romero R., Sukhatme V.P., Letarte M. and Karumanchi S.A. (2006). Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642-649.
113. Walshe T.E., Dole V.S., Maharaj A.S., Patten I.S., Wagner D.D. and D'Amore P.A. (2009). Inhibition of VEGF or TGF-{β} signaling activates endothelium and increases leukocyte rolling. Arterioscler. Thromb. Vasc. Biol. 29, 1185-1192.
114. Walshe T.E., Saint-Geniez M., Maharaj A.S., Sekiyama E., Maldonado A.E. and D'Amore P.A. (2009). TGF-β is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One 4, e5149.
115. Watabe T., Nishihara A., Mishima K., Yamashita J., Shimizu K., Miyazawa K., Nishikawa S. and Miyazono K. (2003). TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J. Cell Biol. 163, 1303-1311.
116. Wu M.Y. and Hill C.S. (2009). TGF-β superfamily signaling in embryonic development and homeostasis. Dev. Cell 16, 329-343.
117. Yang J., Davies R.J., Southwood M., Long L., Yang X., Sobolewski A., Upton P.D., Trembath R.C. and Morrell N.W. (2008). Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ. Res. 102, 1212-1221.
118. Yang J., Li X., Al-Lamki R.S., Southwood M., Zhao J., Lever A.M., Grimminger F., Schermuly R.T. and Morrell N.W. (2010). Smaddependent and Smad-independent induction of Id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ. Res. 107, 252-262.
119. Yang X., Castilla L.H., Xu X., Li C., Gotay J., Weinstein M., Liu P.P. and Deng C.X. (1999). Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development 126, 1571-1580.
120. Yang X., Long L., Southwood M., Rudarakanchana N., Upton P.D., Jeffery T.K., Atkinson C., Chen H., Trembath R.C. and Morrell N.W. (2005). Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ. Res. 96, 1053-1063.
121. Young B.C., Levine R.J. and Karumanchi S.A. (2010). Pathogenesis of preeclampsia. Annu. Rev. Pathol. 5, 173-192.
122. Zhang F., Tsai S., Kato K., Yamanouchi D., Wang C., Rafii S., Liu B. and Kent K.C. (2009). Transforming growth factor-β promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J. Biol. Chem. 284, 17564-17574.